Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Benchmark Holdings ( (GB:BMK) ) has shared an announcement.
Benchmark Holdings reported resilient Q4 FY24 financial results amidst challenging conditions, particularly in the Advanced Nutrition and Genetics sectors. The company recorded total revenues of £36.8 million, a slight increase over the previous year, attributed to strong performance in Advanced Nutrition despite challenging global shrimp markets. The Genetics business, held for disposal, also showed steady results. However, revenues in the Health sector decreased due to a pause in Ectosan® Vet and CleanTreat® activities. Benchmark has maintained financial discipline, reducing operating costs by 35% compared to the prior year, and has positioned itself for future growth with ongoing efforts to streamline its structure and improve profitability.
More about Benchmark Holdings
Benchmark Holdings is a leading aquaculture biotechnology company focused on driving sustainability in the industry by providing products and solutions that enhance yield, growth, and animal health and welfare. With a global presence in 25 countries, Benchmark serves major aquaculture markets worldwide.
YTD Price Performance: -1.03%
Average Trading Volume: 117,219
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £249.3M
See more insights into BMK stock on TipRanks’ Stock Analysis page.
